How to get tesamorelin peptide: the legal, evidence-based routes

Last updated 2026-07-24

Is tesamorelin available without a prescription?

No. Tesamorelin is a prescription-only drug in the United States, whether you get the FDA-approved brand or a compounded version. The approved product, sold under the brand name Egrifta (and the reformulated Egrifta SV), is indicated specifically for the reduction of excess abdominal fat in people with HIV-associated lipodystrophy, a condition of fat redistribution tied to antiretroviral therapy ^[1][2]. That narrow approval matters more than most buyers realize. It means the phase 3 evidence backing tesamorelin, two pooled multicenter, double-blind, placebo-controlled trials with safety extension data, was built specifically in people with HIV and excess visceral fat, not in the general population chasing body composition changes ^[1]. Any use outside that population is off-label, which is legal for a doctor to prescribe but is not what the drug was proven for in registration trials. Websites selling tesamorelin vials as "research chemicals" or "not for human consumption" are working around the prescription requirement, not around the science. Nothing about the peptide's actual pharmacology changes because a listing avoids the word "prescription." You're just losing the physician evaluation, the pharmacy quality control, and any legal recourse if the product is mislabeled or contaminated.

What's the difference between brand-name Egrifta and compounded tesamorelin?

Egrifta SV is the FDA-approved, name-brand version, manufactured under full FDA drug approval standards and tested in the trials that earned that approval ^[1][2]. Compounded tesamorelin is a version prepared by a licensed compounding pharmacy from bulk tesamorelin acetate, typically at a lower price point, but it is not FDA-approved as a finished product. Compounding is legal under federal law when done by licensed pharmacies following specific rules. Section 503A of the Food, Drug, and Cosmetic Act (21 U.S.C. 353a) allows state-licensed pharmacies to compound drugs for individual patients with a valid prescription, and FDA maintains lists of bulk substances that can be used this way ^[3][4][5]. Larger 503B outsourcing facilities compound under a separate set of rules and their own bulk substances list under 21 CFR 216.24. The practical tradeoff: brand Egrifta SV carries FDA manufacturing oversight and the exact trial-tested formulation, but it costs more. Compounded tesamorelin costs less and is often what telehealth clinics dispense for off-label use, but its potency, sterility, and consistency depend entirely on the individual pharmacy's compliance, not on FDA product review. See our tesamorelin cost breakdown for what each route actually runs. Ask any compounding pharmacy for a current certificate of analysis before you accept a vial. If they won't provide one, that's a hard pass.

How do I get a tesamorelin prescription?

You need an evaluation by a licensed prescriber, in person or via telehealth, who reviews your medical history and decides whether tesamorelin is appropriate. For the FDA-approved indication, that means a clinician confirming HIV status and lipodystrophy, usually alongside an HIV specialist or endocrinologist already managing that care ^[6][7]. For off-label use (visceral fat reduction or GH support outside the HIV-lipodystrophy population), a prescriber can still legally write for compounded tesamorelin after reviewing your labs and goals, but you should know this falls outside the specific trial population studied in the two key phase 3 trials ^[1]. A responsible clinician will check baseline IGF-1, ask about active malignancy history, and screen for pituitary or hypothalamic disease before prescribing, since tesamorelin works by stimulating endogenous growth hormone release through the GHRH pathway ^[2]. Telehealth platforms have made this step faster. Many now handle the intake questionnaire, a clinician video or async review, the prescription, and shipping from a partnered pharmacy in one workflow. That's a legitimate model as long as a real prescriber is actually reviewing your case, more than rubber-stamping a form. Tesamorelin Co's provider-reviewed directory points readers toward that kind of vetted pathway rather than anonymous vial sellers.

What did the phase 3 trials actually show?

The core evidence is a pooled analysis of two multicenter, double-blind, placebo-controlled phase 3 trials in HIV-infected patients with excess abdominal fat, including safety extension data, published in the Journal of Clinical Endocrinology and Metabolism ^[1]. Tesamorelin reduced visceral adipose tissue relative to placebo, and multiple downstream analyses of this same trial population have since looked at liver fat, inflammation, and cognition. A 2019 randomized, double-blind, multicenter trial found tesamorelin reduced hepatic fat fraction and, unlike the placebo arm, prevented progression of liver fibrosis in HIV patients with nonalcoholic fatty liver disease ^[2]. A separate analysis linked visceral fat reduction on tesamorelin to improved liver enzyme levels in the same HIV population ^[6]. Inflammatory marker changes have also tracked with visceral fat loss on treatment ^[8]. A 2021 study reported that tesamorelin improves fat quality (reducing the density and inflammatory character of remaining fat tissue) independent of how much fat mass actually changes ^[9], and a 2026 meta-analysis of randomized controlled trials pooled body composition, hepatic fat, and metabolic safety outcomes across the tesamorelin trial base in HIV-associated lipodystrophy ^[10]. Newer work has extended into neurocognitive outcomes: a 2025 study in the Journal of Infectious Diseases examined tesamorelin's effects on neurocognitive impairment in people with HIV and abdominal obesity ^[11], and a 2024 AIDS journal study specifically evaluated efficacy and safety in people with HIV on modern integrase inhibitor regimens ^[12], since HIV treatment itself has changed substantially since the original phase 3 program. None of these later analyses expand the approved indication. They deepen understanding of mechanism and secondary outcomes within the same HIV-associated lipodystrophy population the drug was approved for.

What is tesamorelin approved to treat, exactly?

Tesamorelin is FDA-approved for one specific indication: reduction of excess abdominal fat in HIV-infected patients with lipodystrophy ^[1][2]. It works as a growth hormone-releasing hormone (GHRH) analogue, stimulating the pituitary to release the patient's own growth hormone rather than supplying synthetic GH directly ^[13]. Lipodystrophy itself is a diagnosis, more than a cosmetic complaint. Clinical guidance on diagnosing lipodystrophy syndromes describes characteristic fat redistribution patterns, and endocrine society guidance on approaching patients with lipodystrophy outlines the broader workup a clinician should do before assuming tesamorelin is the right tool ^[14][7]. General visceral fat reduction in people without HIV, anti-aging use, or bodybuilding-style "GH support" are all off-label uses. That doesn't make them illegal for a doctor to prescribe, but it does mean the phase 3 safety and efficacy data doesn't directly transfer. If your reason for wanting tesamorelin is athletic recovery or general midlife body composition change rather than HIV-associated lipodystrophy, read the tesamorelin evidence overview first so you know exactly what has and hasn't been studied in your situation.

What does tesamorelin dosing look like once I have a prescription?

The approved dosing and injection protocol comes from the same phase 3 program discussed above, and pharmacokinetic modeling has since refined understanding of how the drug behaves across different patient groups. A 2015 population pharmacokinetic analysis in Clinical Pharmacokinetics modeled tesamorelin exposure in both HIV-infected patients and healthy subjects, informing dosing consistency across populations ^[15]. A post hoc analysis of the phase 3 placebo-controlled trial specifically compared outcomes in patients with and without dorsocervical fat pads (the so-called "buffalo hump" sometimes seen in lipodystrophy), finding the drug's effect on abdominal visceral fat held regardless of that additional feature ^[16]. Dosing specifics, injection site rotation, and what to do if you miss a dose are detailed on our tesamorelin dosage page, and if you want to work out your own schedule from a compounded vial's concentration, the tesamorelin dosage calculator walks through the math. Reconstitution technique matters too: tesamorelin is a lyophilized powder that has to be mixed with bacteriostatic water correctly to stay stable, which we cover in the tesamorelin reconstitution guide.

What are the real safety risks I should ask my doctor about?

The most consistently reported adverse effects across the tesamorelin trial literature are injection site reactions, joint pain, swelling from fluid retention, and increases in blood glucose, since raising GH and IGF-1 can worsen insulin resistance ^[2][13]. A 2012 clinical review specifically flagged glucose monitoring as a practical concern for patients starting therapy ^[17]. Because tesamorelin stimulates GH release through the GHRH pathway, it carries the same theoretical concerns as other GH-axis therapies around active malignancy: growth hormone and IGF-1 can support tumor growth, so a personal history of active cancer is a standard contraindication discussion topic with a prescriber ^[13]. This is exactly the kind of history a proper intake exam should screen for; it is not something a self-directed online purchase can check for you. Our tesamorelin peptide side effects page goes through the fuller list, including how side effect rates compared between drug and placebo arms in the phase 3 data, and what routine labs a prescriber typically orders (IGF-1, fasting glucose or HbA1c) to monitor you on treatment.

Can I buy tesamorelin peptide online without a doctor?

You can find listings that will ship you a vial labeled "tesamorelin acetate, research use only" without any prescription or medical review. That doesn't make it a legitimate or safe way to get the drug. Those products sidestep both FDA drug approval and the pharmacy compounding framework that governs 503A and 503B facilities under federal law ^[3][4][5]. There's no requirement that they contain the labeled peptide at the labeled concentration, no sterility testing standard they're held to, and no clinician screening you for the contraindications above. A 2021 paper in Drug Testing and Analysis on detecting GHRH synthetic analogs notes these compounds are also monitored in anti-doping contexts, which tells you something about how seriously misuse and mislabeling are taken in sports medicine circles ^[18]. If cost is the real obstacle to going the legitimate route, compounded tesamorelin through a licensed pharmacy is usually the actual affordable option, not an unregulated import. Compare real numbers on the tesamorelin cost page before deciding a research-chemical vial is your only choice.

How does compounding pharmacy law actually work for tesamorelin?

Federal law splits compounding into two tracks. Section 503A (21 U.S.C. 353a) covers traditional pharmacy compounding for an individual patient with a valid prescription, using bulk substances on FDA's 503A bulks list under 21 CFR 216.23 ^[3][4][5]. Section 503B covers larger outsourcing facilities that can compound in batches without a patient-specific prescription in some cases, governed by a separate bulks list under 21 CFR 216.24. FDA's guidance on bulk drug substances used in compounding under section 503A lays out which substances meet the statutory criteria for use, and the agency separately maintains and updates a list of bulk substances nominated for compounding use that have not yet been added ^[3]. This is the regulatory machinery that determines whether a given batch of compounded tesamorelin was legally sourced in the first place, and it's worth asking any pharmacy or telehealth provider which track they operate under. A legitimate compounding pharmacy will be able to tell you this without hesitation. If a seller can't explain whether they're 503A or 503B, or dodges the question entirely, that's a real warning sign, not a technicality.

What should I actually do if I want tesamorelin for visceral fat reduction?

Start with an honest conversation about which category you're in. If you have HIV-associated lipodystrophy, tesamorelin has direct phase 3 trial support for your exact situation ^[1][2], and brand Egrifta SV or a properly compounded equivalent prescribed by your HIV care team is the straightforward path. If you don't have HIV-associated lipodystrophy and you're interested in visceral fat reduction generally, be clear-eyed that you're in off-label territory. That's not disqualifying, plenty of off-label prescribing is routine and reasonable, but it means asking your prescriber directly what evidence they're relying on for your case versus the trial population the drug was actually tested in. Either way, the mechanics are the same: get evaluated by a licensed prescriber, get baseline labs, get a prescription, and fill it through a real pharmacy, brand or compounded, that can show you sourcing and testing documentation. Tesamorelin Co's provider-reviewed pathway connects readers to that kind of vetted intake and a named fulfilling pharmacy partner rather than an anonymous listing, which is the difference between buying a drug and buying a gamble.

Frequently asked questions

Do you need a prescription for tesamorelin?

Yes. Tesamorelin requires a prescription in the United States whether you get the FDA-approved brand Egrifta SV or a compounded version from a licensed pharmacy. There is no legal over-the-counter path. Sellers offering it as an unregulated "research chemical" are avoiding the prescription requirement, not proving the drug is safe to self-administer without medical screening.

What is tesamorelin actually FDA-approved for?

Tesamorelin is FDA-approved specifically to reduce excess abdominal fat in HIV-infected patients with lipodystrophy, based on pooled phase 3 double-blind, placebo-controlled trial data ^[1][2]. It is not approved for general fat loss, anti-aging, or athletic performance; those uses are off-label, meaning a doctor can prescribe it but the core trial evidence doesn't directly cover that population.

Is compounded tesamorelin the same as Egrifta?

Chemically similar, but not regulated the same way. Egrifta SV is FDA-approved as a finished product tested in the phase 3 trials. Compounded tesamorelin is made by a licensed pharmacy from bulk tesamorelin acetate under 503A or 503B rules (21 U.S.C. 353a; 21 CFR 216.23/216.24), without FDA review of the finished product itself.

Can telehealth doctors prescribe tesamorelin legally?

Yes, if a licensed prescriber genuinely reviews your history, labs, and goals before writing the prescription. Telehealth is a legitimate delivery model for both on-label HIV-lipodystrophy care and off-label prescribing. The legitimacy depends on real clinical review happening, not on the word "telehealth" itself; skip any platform that issues a prescription without meaningful evaluation.

How much does tesamorelin cost with and without insurance?

Costs vary widely between brand Egrifta SV and compounded versions, and insurance coverage generally requires the on-label HIV-lipodystrophy diagnosis. See our dedicated tesamorelin cost breakdown for current price ranges by route, since exact numbers shift by pharmacy and plan and shouldn't be guessed at here.

What are the main side effects of tesamorelin?

Trial data shows injection site reactions, joint pain, and fluid-retention swelling as the most common effects, with blood glucose increases as a monitored concern because raised GH and IGF-1 affect insulin sensitivity ^[2][9][14]. A prescriber should check baseline glucose and IGF-1 and screen for active malignancy history before starting therapy.

Does tesamorelin help with liver fat, more than belly fat?

A 2019 randomized, double-blind, multicenter trial found tesamorelin reduced hepatic fat fraction and prevented liver fibrosis progression in HIV patients with fatty liver disease, versus placebo ^[2]. This has only been studied in the HIV-associated lipodystrophy population, not as a general fatty liver treatment.

Is tesamorelin the same as HGH?

No. Tesamorelin is a growth hormone-releasing hormone (GHRH) analogue, meaning it stimulates your pituitary gland to release your own growth hormone. It does not contain synthetic GH itself. This mechanism is part of why its approval and safety profile differ from direct HGH products.

Can I buy tesamorelin peptide from research chemical websites safely?

Not reliably. These vials skip FDA drug review and the 503A/503B pharmacy compounding oversight that governs legitimate compounded tesamorelin, so there's no guarantee of correct concentration, sterility, or purity. You also lose the medical screening step that catches contraindications like active malignancy or pituitary disease before you inject anything.

What labs does a doctor check before prescribing tesamorelin?

Typically baseline IGF-1 and fasting glucose or HbA1c, plus a history screen for active cancer, pituitary or hypothalamic disease, and pregnancy status. For the on-label HIV-lipodystrophy indication, confirmation of lipodystrophy diagnosis and HIV status/treatment regimen is also part of standard workup ^[10][11].

Does tesamorelin work if I don't have HIV?

The phase 3 approval trials were conducted entirely in people with HIV-associated lipodystrophy, so that's where the direct evidence sits ^[1][2]. Use in people without HIV is off-label; a doctor can still prescribe it, but you should ask what evidence, if any, applies specifically to non-HIV visceral fat reduction before starting.

How long does it take to see results from tesamorelin?

The phase 3 approval trials measured visceral fat changes over defined treatment periods with placebo comparison and safety extension follow-up ^[1]. Individual timelines vary by dose, adherence, and baseline visceral fat, so ask your prescriber for the specific timeframe used in the trial data relevant to your situation rather than assuming a fixed number of weeks.

Sources

1. PubMed, Journal of Clinical Endocrinology and Metabolism (2010), PMID 20554713: Pooled analysis of two multicenter, double-blind, placebo-controlled phase 3 trials with safety extension data supporting tesamorelin's approval for reducing excess abdominal fat in HIV-associated lipodystrophy.
2. PubMed, The Lancet HIV (2019), PMID 31611038: Randomized, double-blind, multicenter trial found tesamorelin reduced hepatic fat fraction and prevented liver fibrosis progression versus placebo in HIV-associated NAFLD.
3. PubMed, AIDS (2017), PMID 28832410: Visceral fat reduction with tesamorelin was associated with improved liver enzyme levels in HIV patients.
4. PubMed, AIDS (2011), PMID 21516030: Tesamorelin's effects on inflammatory markers in HIV patients with excess abdominal fat tracked with visceral fat reduction.
5. PubMed, AIDS (2021), PMID 33756511: Tesamorelin improves fat quality independent of changes in total fat quantity.
6. PubMed, Obesity Research & Clinical Practice (2026), PMID 41545261: Meta-analysis of randomized controlled trials on tesamorelin's body composition, hepatic fat, and metabolic safety outcomes in HIV-associated lipodystrophy.
7. PubMed, The Journal of Infectious Diseases (2025), PMID 39813152: Study examined tesamorelin's effects on neurocognitive impairment in persons with HIV and abdominal obesity.
8. PubMed, AIDS (2024), PMID 38905488: Efficacy and safety of tesamorelin evaluated specifically in people with HIV on integrase inhibitor regimens.
9. PubMed, Nature Reviews Drug Discovery (2011), PMID 21283099: Tesamorelin is a growth hormone-releasing hormone (GHRH) analogue that stimulates endogenous pituitary GH release rather than supplying synthetic GH directly.
10. PubMed, Annales d'Endocrinologie (2012), PMID 22748602: Clinical guidance describes the diagnostic workup and characteristic fat redistribution patterns used to diagnose lipodystrophy syndromes.
11. PubMed, The Journal of Clinical Endocrinology and Metabolism (2022), PMID 35137140: Endocrine approach to diagnosing and managing patients with lipodystrophy prior to considering GHRH-analogue therapy.
12. PubMed, Clinical Pharmacokinetics (2015), PMID 25358450: Population pharmacokinetic analysis modeled tesamorelin exposure across HIV-infected patients and healthy subjects.
13. PubMed, Journal of Clinical and Translational Science (2023), PMID 36845310: Post hoc analysis of the phase 3 placebo-controlled trial compared tesamorelin's effect in patients with and without dorsocervical fat.
14. PubMed, The Annals of Pharmacotherapy (2012), PMID 22298602: Clinical review of tesamorelin as a GHRH analogue for HIV-associated lipodystrophy flags glucose monitoring as a practical safety concern.
15. PubMed, Drug Testing and Analysis (2021), PMID 34665524: Research on detecting GHRH synthetic analogs, reflecting anti-doping monitoring of compounds like tesamorelin.
16. FDA, Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act: FDA guidance on which bulk drug substances may legally be used by compounding pharmacies under section 503A.
17. Cornell Law School, Legal Information Institute, 21 U.S.C. 353a: Federal statute governing pharmacy compounding for individual patients with a valid prescription.
18. eCFR, 21 CFR 216.23, the 503A Bulks List: Regulatory list of bulk drug substances approved for use in 503A pharmacy compounding.